| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(15)00459-6 |
| P698 | PubMed publication ID | 26474810 |
| P50 | author | Erik Magnus Ohman | Q60697402 |
| Stefan James | Q86735199 | ||
| Ramin Farzaneh-Far | Q87219572 | ||
| Andrés Iñiguez | Q90628727 | ||
| Gregg W Stone | Q90754539 | ||
| Ori Ben-Yehuda | Q93152543 | ||
| Philippe Généreux | Q96767939 | ||
| Aleksander Żurakowski | Q110727098 | ||
| Giora Weisz | Q114304178 | ||
| Ovidiu Dressler | Q114304200 | ||
| Anna Osmukhina | Q114304252 | ||
| P2093 | author name string | Karen P Alexander | |
| Michael Shechter | |||
| RIVER-PCI investigators | |||
| P2860 | cites work | Heart Disease and Stroke Statistics--2015 Update: A Report From the American Heart Association | Q22241921 |
| Fractional flow reserve versus angiography for guiding percutaneous coronary intervention | Q28306779 | ||
| Incidence, predictors and outcomes of incomplete revascularization after percutaneous coronary intervention and coronary artery bypass grafting: a subgroup analysis of 3-year SYNTAX data | Q34118922 | ||
| The effect of completeness of revascularization on event-free survival at one year in the ARTS trial | Q34534765 | ||
| Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial | Q34544699 | ||
| Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina | Q34547211 | ||
| Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial | Q34569443 | ||
| Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. | Q34571615 | ||
| Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial | Q34578958 | ||
| Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial | Q34637924 | ||
| Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial | Q35175453 | ||
| Impact of incomplete revascularization on long-term mortality after coronary stenting | Q35400124 | ||
| Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine | Q36507053 | ||
| Complete versus incomplete revascularization with coronary artery bypass graft or percutaneous intervention in stable coronary artery disease | Q38034950 | ||
| Residual plaque burden in patients with acute coronary syndromes after successful percutaneous coronary intervention | Q39639374 | ||
| A prospective natural-history study of coronary atherosclerosis | Q41983924 | ||
| Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score | Q42201341 | ||
| Effect of complete revascularization on 10-year survival of patients with stable multivessel coronary artery disease: MASS II trial | Q43855388 | ||
| Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trial | Q44953215 | ||
| Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial | Q45195984 | ||
| On looking at subgroups | Q46112071 | ||
| Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN-TIMI 36 Trial. | Q46828799 | ||
| Prognostic value of "routine" cardiac stress imaging 5 years after percutaneous coronary intervention: the prospective long-term observational BASKET (Basel Stent Kosteneffektivitäts Trial) LATE IMAGING study. | Q51139802 | ||
| Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. | Q51201327 | ||
| Randomized Trial of Preventive Angioplasty in Myocardial Infarction | Q56671779 | ||
| Quantification of Incomplete Revascularization and its Association With Five-Year Mortality in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial Validation of the Residual SYNTAX Score | Q57566909 | ||
| Fractional Flow Reserve–Guided PCI for Stable Coronary Artery Disease | Q61651351 | ||
| Incomplete revascularization in the era of drug-eluting stents: impact on adverse outcomes | Q83888264 | ||
| The ability to achieve complete revascularization is associated with improved in-hospital survival in cardiogenic shock due to myocardial infarction: Manitoba cardiogenic SHOCK Registry investigators | Q84052089 | ||
| P433 | issue | 10014 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | river | Q4022 |
| multicenter clinical trial | Q6934595 | ||
| revascularization | Q7317735 | ||
| placebo | Q269829 | ||
| P304 | page(s) | 136-145 | |
| P577 | publication date | 2015-10-12 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial | |
| P478 | volume | 387 |
| Q50633215 | A Novel Intra-aortic Device Designed for Coronary Blood Flow Amplification in Unrevascularizable Patients. |
| Q33647497 | ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathy |
| Q39164200 | Advancements in pharmacotherapy for angina. |
| Q45300556 | Alpha-crystallin: an ATP-independent complete molecular chaperone toward sorbitol dehydrogenase |
| Q45300561 | Angina and Its Management |
| Q89700406 | Angina: contemporary diagnosis and management |
| Q92501280 | Assessing Prognosis of Acute Coronary Syndrome in Recent Clinical Trials: A Systematic Review |
| Q47190217 | Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials |
| Q60919993 | Cardiovascular drugs attenuated myocardial resistance against ischaemia-induced and reperfusion-induced injury in a rat model of repetitive occlusion |
| Q98902851 | Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial |
| Q38803136 | Experimental and early investigational drugs for angina pectoris |
| Q33734021 | Improvement of Subjective Well-Being by Ranolazine in Patients with Chronic Angina and Known Myocardial Ischemia (IMWELL Study) |
| Q58741622 | Linking cell function with perfusion: insights from the transcatheter delivery of bone marrow-derived CD133 cells in ischemic refractory cardiomyopathy trial (RECARDIO) |
| Q45965347 | Management of Persistent Angina After Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study. |
| Q38957123 | Management of Stable Angina - Current Guidelines: A Critical Appraisal |
| Q39738089 | Management of stable angina: A commentary on the European Society of Cardiology guidelines |
| Q30239853 | Management standards for stable coronary artery disease in India |
| Q30313892 | National disease management guidelines (NVL) for chronic CAD : What is new, what is particularly important? |
| Q38811072 | Overview of Management of Myocardial Ischemia: a Mechanistic-Based Approach |
| Q44284882 | Post PCI Angina: Painful in Many Ways! |
| Q51019687 | Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial. |
| Q38761008 | Ranolazine and Ivabradine: two different modalities to act against ischemic heart disease |
| Q38971758 | Ranolazine for stable angina pectoris |
| Q26765421 | Ranolazine: A Contemporary Review |
| Q55080711 | Ranolazine: A true pluripotent cardiovascular drug or jack of all trades, master of none? |
| Q90104758 | Ranolazine: Multifaceted Role beyond Coronary Artery Disease, a Recent Perspective |
| Q64068775 | Ranolazine: impact on quality of life in patients with stable angina pectoris, results from an observational study in Austria - the ARETHA AT study |
| Q91644973 | Relationship Between Optimism and Outcomes in Patients With Chronic Angina Pectoris |
| Q37217902 | Safety and efficacy of a device to narrow the coronary sinus for the treatment of refractory angina: A single-centre real-world experience |
| Q39034193 | The coronary sinus reducer: clinical evidence and technical aspects. |
| Q38685680 | The year in cardiology 2015: acute coronary syndromes |
| Q38685684 | The year in cardiology 2015: coronary intervention |
| Q96304373 | Treatment of stable ischaemic heart disease: the old and the new |
| Q61454288 | Trimetazidine and Other Metabolic Modifiers |
Search more.